

# Catenin Beta 1 (Beta Catenin or CTNNB1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/CBB39D8D471EEN.html>

Date: September 2022

Pages: 83

Price: US\$ 3,500.00 (Single User License)

ID: CBB39D8D471EEN

## Abstracts

Catenin Beta 1 (Beta Catenin or CTNNB1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

According to the recently published report 'Catenin Beta 1 - Drugs In Development, 2022'; Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 23 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes.

Catenin Beta 1 (Beta Catenin or CTNNB1) - Catenin beta-1 or  $\beta$ -catenin is a protein that is encoded by the CTNNB1 gene. In the presence of Wnt ligand, CTNNB1 acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. It is involved in the regulation of cell adhesion, CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. It also acts as a negative regulator of centrosome cohesion. It blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2.

The report 'Catenin Beta 1 - Drugs In Development, 2022' outlays comprehensive information on the Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 7 and 7 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 3 molecules, respectively.

Report covers products from therapy areas Oncology, Respiratory, Dermatology, Gastrointestinal, Infectious Disease and Non Malignant Disorders which include indications Colorectal Cancer, Breast Cancer, Liver Cancer, Solid Tumor, Hepatocellular Carcinoma, Melanoma, Unspecified Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Colon Cancer, Gastric Cancer, Idiopathic Pulmonary Fibrosis, Lung Cancer, Neuroendocrine Tumors, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Anaplastic Thyroid Cancer, Bladder Cancer, Blood Cancer, Brain Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Coronavirus Disease 2019 (COVID-19), Endometrial Cancer, Gallbladder Cancer, Gastrointestinal Tract Cancer, Gastrointestinal Tumor, Head And Neck Cancer, Hemangiomas, Hematological Tumor, Hepatic (Liver) Tumor, Kidney Cancer (Renal Cell Cancer), Leukemia, Liver Cirrhosis, Malignant Mesothelioma, Metastatic Adenocarcinoma of The Pancreas, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Scar and Small-Cell Lung Cancer.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Catenin Beta 1 (Beta Catenin or CTNNB1)

The report reviews Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics and enlists all their major and minor projects

The report assesses Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Catenin Beta 1 (Beta Catenin or CTNNB1) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Catenin Beta

## 1 (Beta Catenin or CTNNB1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Catenin Beta 1 (Beta Catenin or CTNNB1) - Overview

Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Catenin Beta 1 (Beta Catenin or CTNNB1) - Companies Involved in Therapeutics Development

3+2 Pharma LLC

Agastiya Biotech LLC

Aileron Therapeutics Inc

Circle Pharma Inc

Dicerna Pharmaceuticals Inc

Entrada Therapeutics Inc

f5 Therapeutics Inc

Fog Pharmaceuticals Inc

iBeCa Therapeutics

MD2 Biosciences Inc

PRISM Pharma Co Ltd

Propanc Biopharma Inc

Sapience Therapeutics Inc

Stemsynergy Therapeutics Inc

Sumitomo Dainippon Pharma Oncology, Inc

Venn Therapeutics LLC

WntRx Pharmaceuticals Inc

Catenin Beta 1 (Beta Catenin or CTNNB1) - Drug Profiles

AB-01 - Drug Profile

Product Description

Mechanism Of Action

History of Events

## Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Oncology - Drug Profile

Product Description

Mechanism Of Action

History of Events

## BBI-801 - Drug Profile

Product Description

Mechanism Of Action

History of Events

## Beta catenin Degradar Antibody - Drug Profile

Product Description

Mechanism Of Action

## Beta-Catenin Transcriptional Complex Inhibitors - Drug Profile

Product Description

Mechanism Of Action

## CBP/beta-Catenin Antagonist - Drug Profile

Product Description

Mechanism Of Action

History of Events

## exisulind - Drug Profile

Product Description

Mechanism Of Action

## FOG-001 - Drug Profile

Product Description

Mechanism Of Action

## nefopam hydrochloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

## Oligonucleotides for Hepatoblastoma - Drug Profile

Product Description

Mechanism Of Action

## PRI-724 - Drug Profile

Product Description

Mechanism Of Action

History of Events

## PRP - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit Beta Catenin and BCL9 for Colorectal Cancer - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit Beta Catenin for Colorectal Cancer and Brain Cancer - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit Beta Catenin for Oncology - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit Beta Catenin for Unspecified Cancers - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit CTNNB1 for Unspecified Cancer - Drug Profile

Product Description

Mechanism Of Action

ST-316 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Synthetic Peptides to Inhibit Beta Catenin for Oncology - Drug Profile

Product Description

Mechanism Of Action

Synthetic Peptides to Inhibit Beta Catenin for Solid Tumor and Blood Cancer - Drug Profile

Product Description

Mechanism Of Action

History of Events

Wnt-Driven Diseases - Drug Profile

Product Description

Mechanism Of Action

WNTinib - Drug Profile

Product Description

Mechanism Of Action

WX-024 - Drug Profile

Product Description

Mechanism Of Action

Catenin Beta 1 (Beta Catenin or CTNNB1) - Dormant Products

Catenin Beta 1 (Beta Catenin or CTNNB1) - Product Development Milestones

Featured News & Press Releases

Sep 08, 2022: Propanc Biopharma reports significant effects of PRP against the tumor microenvironment

Aug 23, 2022: Propanc Biopharma synthesizes recombinant trypsinogen & chymotrypsinogen via POP1 joint research & drug discovery program

Jul 28, 2022: Propanc Biopharma's CSO reflects on unique anti-cancer effects of PRP discovered over past decade

Jul 12, 2022: Propanc Biopharma's CEO believes lead asset could unlock value as PRP advances to phase I, first-in-human study in advanced cancer patients

Jul 05, 2022: Propanc Biopharma's CEO comments on the 39 granted patents and 26 patent applications under examination in key global jurisdictions

Jun 22, 2022: Propanc Biopharma's CSO hails dostarlimab's impressive results whilst acknowledging more work to be done in the fight against cancer

Jun 01, 2022: Propanc Biopharma believes PRP reduced toxicity will impact cancer patient lives significantly

May 26, 2022: Propanc Biopharma presents 100 years of clinical evidence for "novel" enzyme therapeutic approach to treat cancer

May 18, 2022: Propanc Biopharma undertaking PRP manufacturing & development for human use

May 11, 2022: Propanc Biopharma offers a novel way to stop cancer

May 03, 2022: Agastiya Biotech receives FDA Orphan Drug Designation for AB001 for pancreatic cancer and Acute Myeloid Leukemia (AML)

May 02, 2022: Propanc Biopharma purchases pharma grade raw materials for PRP manufacture in preparation for phase I first-in-human study

Apr 13, 2022: Propanc Biopharma's management explains why they believe cancer patients are likely to respond to PRP treatment

Apr 11, 2022: Sapience Therapeutics presents late-breaking data on ST316 at AACR 2022

Mar 22, 2022: Propanc Biopharma receives notice of allowance for method to treat cancer stem cells from the US Patent & Trademark Office

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us



## Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

## I would like to order

Product name: Catenin Beta 1 (Beta Catenin or CTNNB1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/CBB39D8D471EEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CBB39D8D471EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

